240 related articles for article (PubMed ID: 23952687)
1. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
[TBL] [Abstract][Full Text] [Related]
2. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
3. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Zaitone SA; Hammad LN; Farag NE
Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice.
Liu Q; Zhu D; Jiang P; Tang X; Lang Q; Yu Q; Zhang S; Che Y; Feng X
Behav Brain Res; 2019 Jul; 367():10-18. PubMed ID: 30922940
[TBL] [Abstract][Full Text] [Related]
6. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Borah A; Mohanakumar KP
J Pineal Res; 2009 Nov; 47(4):293-300. PubMed ID: 19796048
[TBL] [Abstract][Full Text] [Related]
7. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Bankiewicz KS; Daadi M; Pivirotto P; Bringas J; Sanftner L; Cunningham J; Forsayeth JR; Eberling JL
Exp Neurol; 2006 Feb; 197(2):363-72. PubMed ID: 16337943
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
9. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
[TBL] [Abstract][Full Text] [Related]
10. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
[TBL] [Abstract][Full Text] [Related]
11. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
King JM; Muthian G; Mackey V; Smith M; Charlton C
Life Sci; 2011 Oct; 89(17-18):638-43. PubMed ID: 21871902
[TBL] [Abstract][Full Text] [Related]
12. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
13. L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Suarez LM; Solis O; Aguado C; Lujan R; Moratalla R
Cereb Cortex; 2016 Oct; 26(11):4253-4264. PubMed ID: 27613437
[TBL] [Abstract][Full Text] [Related]
14. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity.
Fornai F; Battaglia G; Gesi M; Giorgi FS; Orzi F; Nicoletti F; Ruggieri S
Brain Res; 2000 Dec; 887(1):110-7. PubMed ID: 11134595
[TBL] [Abstract][Full Text] [Related]
15. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
Fredriksson A; Palomo T; Archer T
J Neural Transm (Vienna); 1999; 106(9-10):889-909. PubMed ID: 10599871
[TBL] [Abstract][Full Text] [Related]
16. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
17. The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
Liu Q; Zhang S; Zhu D; Tang X; Che Y; Feng X
Behav Brain Res; 2020 Feb; 379():112337. PubMed ID: 31697983
[TBL] [Abstract][Full Text] [Related]
18. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
Goshima Y; Misu Y; Arai N; Misugi K
Jpn J Pharmacol; 1991 Jan; 55(1):93-100. PubMed ID: 1645816
[TBL] [Abstract][Full Text] [Related]
19. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Viaro R; Marti M; Morari M
Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
[TBL] [Abstract][Full Text] [Related]
20. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]